PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer
Breast Cancer

About this trial
This is an interventional diagnostic trial for Breast Cancer focused on measuring Comparison of imaging modalities, predict the effectiveness of neoadjuvant chemotherapy
Eligibility Criteria
Inclusion Criteria: Breast cancer scheduled for neoadjuvant chemotherapy followed by surgery Exclusion criteria: Indicated chemotherapy without that a curative tumorectomies is foreseen(planned) Patient presenting an evolutionary infectious or inflammatory pathology, including an inflammatory breast cancer, being able to be source(spring) of false-positive results(profits) in TEP-FDG Patient in the course of radiotherapy or of chemotherapy or operated at the level of the thorax in 4 weeks preceding the date foreseen(planned) by the examination TEP (pose(installation) of implantable room(chamber) excludes) Diabetic waits Patient already includes in the other protocols of search(research) for Nuclear Medicine or for imaging using ionization radiations Patient not having given her lit(enlightened) assent Wait among which the surveillance TEP or the MRI during the chemotherapy will be impossible (that is by geographical or professional imperative, or if contraindication in the MRI, ex: port(bearing) of a pacemaker, cochlear magnetic implants, metal foreign bodies cf protocol) Of less than 18 years old or pregnant patient. Breast cancer stage(stadium) IV Biopsy on the already realized mammary tumor, for the period(delay) lower than 15 j. In case of alcoholic poisoning or of antecedents of reaction to the injection of ethanol: not inclusion to be discussed.
Sites / Locations
- Hôpital TENON
Arms of the Study
Arm 1
Experimental
1
Fluoro-L-thymidine-(18F)